Tideglusib is under investigation for multiple applications: Alzheimer's disease and progressive supranuclear palsy. As of 2017 it was undergoing Phase IIa and IIb clinical trials.The first trial to be published (in English) was Phase II and demonstrated that tideglusib was well tolerated, except for some moderate, asymptomatic, fully reversible increases in liver enzymes.Tooth repair mechanisms that promotes dentine reinforcement of a sponge structure until the sponge biodegrades, leaving a solid dentine structure. In 2016, the results of animal studies were reported in which 0.14 mm holes in mouse teeth were permanently filled. Tideglusib is being studied in Phase II clinical trials as a treatment for congenital/juvenile-onset myotonic muscular dystrophy type I
Complaint
